CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 194 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.14 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,240,349 | +47.1% | 83,189 | +8.1% | 0.00% | – |
Q2 2023 | $843,244 | +164.3% | 76,957 | +110.4% | 0.00% | – |
Q1 2023 | $319,022 | +1287.1% | 36,585 | +401.0% | 0.00% | – |
Q1 2022 | $23,000 | +21.1% | 7,302 | +31.4% | 0.00% | – |
Q4 2021 | $19,000 | -5.0% | 5,558 | 0.0% | 0.00% | – |
Q3 2021 | $20,000 | -16.7% | 5,558 | 0.0% | 0.00% | – |
Q2 2021 | $24,000 | -44.2% | 5,558 | -41.2% | 0.00% | – |
Q1 2021 | $43,000 | -20.4% | 9,457 | 0.0% | 0.00% | – |
Q4 2020 | $54,000 | +22.7% | 9,457 | +54.9% | 0.00% | – |
Q3 2020 | $44,000 | +46.7% | 6,106 | -28.2% | 0.00% | – |
Q2 2020 | $30,000 | +50.0% | 8,503 | -36.7% | 0.00% | – |
Q1 2020 | $20,000 | -37.5% | 13,434 | -18.1% | 0.00% | – |
Q4 2019 | $32,000 | -54.9% | 16,404 | +19.3% | 0.00% | – |
Q3 2019 | $71,000 | -27.6% | 13,746 | 0.0% | 0.00% | – |
Q2 2019 | $98,000 | -30.0% | 13,746 | +29.7% | 0.00% | – |
Q1 2019 | $140,000 | +79.5% | 10,595 | +6.6% | 0.00% | – |
Q4 2018 | $78,000 | -29.1% | 9,941 | 0.0% | 0.00% | – |
Q3 2018 | $110,000 | -17.9% | 9,941 | 0.0% | 0.00% | – |
Q2 2018 | $134,000 | – | 9,941 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |